VIP Peptide (Vasoactive Intestinal Peptide): MCAS, Long COVID & Inflammation Guide 2026

Vasoactive Intestinal Peptide is a 28-amino-acid neuropeptide that belongs to the glucagon/secretin superfamily — a diverse family of signalling molecules that includes glucagon, secretin, GIP, GLP-1, PACAP, and PHI, all sharing structural motifs at the N-terminus. VIP is encoded by the VIP gene located on chromosome 6p24 in humans, and the protein is cleaved from a larger precursor (pre-pro-VIP) that also yields peptide histidine methionine (PHM-27) — a related bioactive fragment.

VIP is expressed throughout the body, but it is most concentrated in the nervous system (particularly the autonomic nervous system and enteric nervous system), the gastrointestinal tract, the respiratory tract, and — critically for immune research — in immune cells themselves, including lymphocytes and macrophages that can both synthesise and respond to VIP.

Receptor System: VPAC1 and VPAC2

VIP exerts its effects through two G-protein coupled receptors: VPAC1 (VIPR1) and VPAC2 (VIPR2), both of which signal primarily through adenylyl cyclase activation and cyclic AMP (cAMP) accumulation. VPAC1 is ubiquitously expressed — it is found in the lung, liver, intestine, and on most immune cells. VPAC2 has a more restricted distribution, with high expression in the brain, smooth muscle, and pancreas. The cAMP-mediated signalling cascade downstream of both receptors activates PKA, which phosphorylates CREB and other transcription factors, ultimately suppressing NF-κB-driven inflammatory gene expression ^[3].

Physiological Functions

In classical physiology, VIP is known for:

• Vasodilation — relaxation of vascular smooth muscle, reducing peripheral resistance
• Bronchodilation — relaxation of airway smooth muscle, relevant to asthma research
• Intestinal secretion — stimulation of fluid and electrolyte secretion in the gut
• Circadian rhythm regulation — VIP neurons in the suprachiasmatic nucleus (SCN) are the primary pacemaker synchronisation signal between individual SCN cells
• Immune modulation — suppression of Th1 and Th17 responses, promotion of regulatory T-cell (Treg) differentiation, and modulation of macrophage polarisation toward the anti-inflammatory M2 phenotype

The immune-modulatory functions are particularly relevant to understanding VIP's potential therapeutic applications. Research by Delgado and Ganea has documented in detail how VIP shifts the immune response away from destructive inflammation: it suppresses the production of TNF-α, IL-6, IL-12, and IFN-γ while inducing IL-10, TGF-β, and the conditions that favour Treg expansion ^[3]. Mast cells express both VPAC1 and VPAC2 receptors, and the VIP-mast cell interaction is a bidirectional relationship — VIP can stimulate mast cell migration and certain functions at high concentrations, but at physiological levels it appears to raise the threshold for degranulation, providing a natural braking mechanism on mast cell hyperreactivity.

Mast Cell Activation Syndrome (MCAS) is characterised by episodic, often unpredictable degranulation of mast cells — the sentinel immune cells that reside in virtually every tissue but are especially concentrated at tissue-environment interfaces: the gut, skin, lungs, and blood-brain barrier. When mast cells degranulate inappropriately, they release a torrent of mediators: histamine, tryptase, chymase, prostaglandins (particularly PGD2), leukotrienes, and a cascade of pro-inflammatory cytokines including TNF-α and IL-6. The result for patients is a wide spectrum of symptoms — flushing, hives, GI distress, neurological symptoms, fatigue, and in severe cases, anaphylaxis.

The connection between VIP and MCAS operates at multiple levels. First and most fundamentally: mast cells express both VPAC1 and VPAC2 receptors, meaning they are direct targets of VIP signalling. When VIP binds these receptors and raises intracellular cAMP, it suppresses the calcium-dependent signalling cascade that drives degranulation. This is the endogenous brake on mast cell activation — and when VIP levels are chronically low, that brake is compromised.

Dr. Lawrence Afrin, one of the foremost clinical researchers in MCAS, has documented that many MCAS patients have measurably low serum VIP levels ^[4]. This creates a self-reinforcing cycle: low VIP leads to heightened mast cell reactivity, which leads to chronic inflammation and tissue damage, which further impairs the VIPergic neurons that produce endogenous VIP. Understanding this cycle has led some clinicians working in the MCAS space to explore VIP replacement as part of a comprehensive approach.

CIRS and the Shoemaker Connection

Dr. Ritchie Shoemaker's work on Chronic Inflammatory Response Syndrome (CIRS) — biotoxin-driven inflammatory illness caused by water-damaged buildings, Lyme disease, ciguatera, and other biotoxin sources — converges with MCAS research at the level of VIP. In CIRS patients, Shoemaker consistently finds suppressed VIP levels (often well below the normal range of 23–63 pg/mL), elevated MMP-9, elevated TGF-β1, and suppressed MSH (alpha-melanocyte-stimulating hormone). His observational cohort data, published in Neurotoxicol Teratol, showed that administering intranasal VIP as the final protocol step led to significant reductions in MMP-9 and TGF-β1, increases in MSH, and improvements in cognitive function, fatigue, and exercise tolerance ^[1].

Critically, Shoemaker's protocol also provided a cautionary lesson: administering VIP prematurely — before clearing biotoxin burden, MARCoNS nasal colonisation, and mold exposure — can precipitate severe reactions. The sequence matters. VIP appears to be most beneficial and safest when the underlying inflammatory drivers are first addressed.

Few areas in peptide research have moved as rapidly as the investigation of VIP in Long COVID. The post-acute sequelae of SARS-CoV-2 infection (PASC) — commonly called Long COVID — affects an estimated 10–30% of COVID-19 survivors and is characterised by a constellation of symptoms that overlap extensively with conditions where VIP deficiency is implicated: post-exertional malaise, cognitive dysfunction ("brain fog"), autonomic dysfunction including Postural Orthostatic Tachycardia Syndrome (POTS), mast cell activation, and gut dysbiosis.

The convergence of Long COVID and VIP research was accelerated by several landmark findings. A 2022 study published in Gut documented that Long COVID patients with persistent GI dysfunction had measurably suppressed VIP signalling in intestinal tissue. More strikingly, 2023 data from Yale investigators showed that VIPergic nerve fibers in small intestine biopsies were structurally depleted in Long COVID patients — not just functionally suppressed, but anatomically reduced. This suggests that SARS-CoV-2 (or the immune response it provokes) may directly damage the VIPergic nervous system, creating a structural deficit that persists long after viral clearance.

The Spike Protein Hypothesis

A compelling mechanistic hypothesis has emerged suggesting that the SARS-CoV-2 spike protein — or antibodies generated against it — may cross-react with or directly damage VIPergic neurons. VIPergic neurons in the autonomic and enteric nervous systems express ACE2, the primary receptor used by SARS-CoV-2 for cell entry, making them plausible direct targets of viral damage. Additionally, the intense neuroinflammation driven by microglial activation in Long COVID creates a hostile environment for VIPergic neurons, which are known to be particularly sensitive to inflammatory insult.

Autonomic Dysfunction and POTS

VIP's role as a vasodilator and autonomic modulator makes it directly relevant to the POTS presentation in Long COVID. VIP is a key co-transmitter in the autonomic nervous system, modulating sympathovagal balance. Research into intranasal VIP for post-COVID dysautonomia is ongoing at several centres as of 2026, with the hypothesis that restoring VIP tone in the autonomic nervous system may help recalibrate the exaggerated sympathetic responses seen in POTS. Early observational data from integrative clinics using the Shoemaker protocol adapted for post-COVID patients has been encouraging, though randomised trial data is still awaited.

The overlap between Long COVID and MCAS is also critical here: studies suggest that 30–50% of Long COVID patients meet criteria for MCAS, and VIP deficiency may be a shared upstream driver connecting both syndromes through the same pathway — loss of the endogenous immune brake that VIP provides.

Among the most systematically documented applications of VIP in clinical practice is Dr. Ritchie Shoemaker's CIRS (Biotoxin Illness) protocol, where intranasal VIP serves as Step 12 — the final and capstone intervention in a sequenced, multi-step treatment algorithm. The protocol was developed over many years of clinical observation and published in peer-reviewed literature, with intranasal VIP formally incorporated after it became available through compounding pharmacies ^[1].

In the Shoemaker protocol, intranasal VIP is administered as 4 sprays (approximately 400 mcg total) four times daily, typically for a period of several months. The primary measurable endpoints are:

• Normalisation of serum VIP levels to the reference range of 23–63 pg/mL
• Reduction in MMP-9 (matrix metalloproteinase-9), a key marker of neuroinflammation
• Reduction in TGF-β1 toward normal range
• Improvement in MSH (alpha-melanocyte-stimulating hormone) levels
• Patient-reported improvement in cognitive function, exercise tolerance, and fatigue

Critical prerequisites that must be completed before VIP administration in the Shoemaker protocol include:

• MARCoNS (Multiple Antibiotic Resistant Coagulase Negative Staphylococci) nasal colonisation cleared
• Active mold/biotoxin exposure eliminated (ERMI score <2 in home environment)
• Prior protocol steps (binders, cholestyramine/Welchol, VCS testing normalisation) completed
• Androgen deficiency addressed where applicable

Administering VIP before completing these steps — particularly before clearing MARCoNS and biotoxin exposure — is reported to cause paradoxical worsening and significant adverse reactions in CIRS patients. The sequencing is not arbitrary; it reflects the observation that VIP's immune-modulatory effects require a stable inflammatory baseline to be beneficial rather than destabilising.

The following information describes what has been used in published research and clinical protocols. It is provided for educational purposes only and does not constitute medical advice, dosing guidance, or a treatment recommendation.

VIP presents unique challenges as a research peptide due to its extremely short half-life in circulation. When administered intravenously, VIP has a plasma half-life of approximately 1–2 minutes due to rapid enzymatic degradation by dipeptidyl peptidase IV (DPP-IV) and neutral endopeptidase. This has historically limited its therapeutic utility by IV routes, except in acute settings. Alternative delivery routes substantially extend the effective duration of action:

• Intranasal (most studied for chronic conditions): The Shoemaker CIRS protocol uses 4 intranasal sprays per administration session (approximately 100 mcg per spray, 400 mcg total), administered 4 times daily. Intranasal delivery provides access to the olfactory nerve and direct CNS pathway, as well as absorption across nasal mucosa. Half-life is substantially extended versus IV.
• Subcutaneous injection: Used in some research trials; allows slower absorption and prolonged tissue exposure versus IV. Dose ranges in published research vary considerably.
• Inhaled: Investigated for pulmonary applications including pulmonary hypertension and cystic fibrosis-related bronchospasm.

VIP research peptides are supplied as lyophilised (freeze-dried) powder, typically in 2 mg vials. Reconstitution is performed with bacteriostatic water (0.9% benzyl alcohol). Once reconstituted, VIP solutions should be stored refrigerated (2–8°C) and used within a short window; degradation is a significant concern at room temperature or when subjected to repeated freeze-thaw cycles. Unused powder should be stored frozen at −20°C or below.

Due to the peptide's lability, researchers pay close attention to purity verification via HPLC and mass spectrometry, as partially degraded VIP sequences can have unpredictable biological activity.

VIP has been administered in multiple human clinical trials and in large observational cohorts within the Shoemaker CIRS protocol, providing a meaningful body of safety data. The overall tolerability profile is generally favourable when used appropriately, but several considerations are important.

Commonly Reported Effects

• Flushing and vasodilation — the most commonly observed effect, consistent with VIP's known pharmacology as a vasodilator. This is typically transient and dose-related.
• Transient hypotension — particularly at higher IV doses. Intranasal administration is associated with much lower rates of clinically significant blood pressure reduction than IV routes, but remains a consideration for individuals with baseline hypotension or autonomic instability.
• Gastrointestinal effects — nausea and diarrhea have been reported at higher doses, again consistent with VIP's native role in stimulating intestinal secretion.
• Local nasal effects — mild irritation or congestion with prolonged intranasal administration.

Contraindications and Cautions

• VIP should not be used by individuals with significant baseline hypotension, as its vasodilatory effects may cause clinically meaningful blood pressure reduction.
• In the context of CIRS treatment, VIP must not be administered until the prerequisite Shoemaker protocol steps are completed. Patients with active biotoxin burden, ongoing mold exposure, or uncleared MARCoNS nasal colonisation may experience significant paradoxical inflammatory reactions when VIP is introduced prematurely.
• Due to its potent immune-modulatory effects on Treg promotion and Th1/Th17 suppression, VIP should be used with caution in individuals with active infections where a robust Th1 response is protective.
• As with all peptide research compounds, immunogenicity (antibody development against the peptide) is a theoretical concern with repeated administration, though it has not been a prominent feature in published VIP research to date ^[3].

Systematic safety data from large randomised controlled trials in the specific populations most interested in VIP (MCAS, Long COVID) remain limited, as most evidence comes from observational cohorts and smaller controlled trials. Individuals considering VIP research protocols should do so under the supervision of a knowledgeable physician who can monitor relevant biomarkers including serum VIP levels, inflammatory markers, and blood pressure.